According to The Insight Partners' research, the Europe Antibody Drug Conjugates Market was valued at US$ 1,990.5 Million in 2023 and is expected to reach US$ 9,598.7 Million by 2031, registering a CAGR of 21.7% from 2023 to 2031.
Expansion into new indications and expanding clinical trial pipeline are among the critical factors attributed to driving the Europe antibody drug conjugates market growth.
The expansion into new indications is creating significant opportunities in the antibody-drug conjugates market. As antibody-drug conjugates are primarily designed to deliver cytotoxic agents directly to cancer cells while sparing healthy tissues, their ability to target specific tumor-associated antigens makes them highly versatile. This versatility allows for exploring antibody-drug conjugate applications beyond their initial indications, i.e., hematological malignancies and certain solid tumors. Many cancers currently lack adequate treatment options, and introducing antibody-drug conjugates targeting new biomarkers can provide innovative therapies for these challenging conditions. For instance, antibody-drug conjugates are being investigated for treating cancers such as breast, lung, and bladder cancers, where traditional therapies may not yield satisfactory results. In April 2025, Daiichi Sankyo's ADC Dato-DXd (DATROWAY) received approval in the European Union for patients with previously treated metastatic hormone receptor-positive, HER2-negative breast cancer. This expansion goes beyond previous lines of therapy and increases the number of patients who can benefit from this ADC. Additionally, the collaboration between pharmaceutical companies and research institutions fosters innovation in antibody-drug conjugate development. These partnerships often focus on identifying novel targets and optimizing linker technologies to enhance the efficacy and safety profiles of conjugates. Moreover, with the discovery and validation of new targets, antibody-drug conjugates are being further investigated for their potential utilization in the treatment of a broader range of cancer types. By addressing unmet medical needs, benefiting from favorable regulatory conditions, capitalizing on the rising prevalence of cancer, and fostering collaborative innovation, antibody-drug conjugates are poised to play a pivotal role in the future of targeted cancer therapies. Thus, an expansion into new indications presents a wealth of opportunities for the antibody-drug conjugates market.
On the contrary, manufacturing challenges hamper the growth of Europe antibody drug conjugates markets.
Europe Antibody Drug Conjugates Market Segmentation Analysis:
- By Technology, the Europe Antibody Drug Conjugates Market is segmented into Cleavable Linker and Non-cleavable Linker. The Cleavable Linker segment is projected to expand at 22.0% CAGR during 2023 - 2031.
- By Application, the Europe Antibody Drug Conjugates Market is segmented into Blood Cancer, Brain Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, and Others. The Breast Cancer segment is projected to expand at 22.6% CAGR during 2023 - 2031.
- By Target, the Europe Antibody Drug Conjugates Market is segmented into HER2, CD22, CD30, and Others. The HER2 segment is projected to expand at 22.4% CAGR during 2023 - 2031.
- By Distribution Channel, the Europe Antibody Drug Conjugates Market is segmented into Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies. The Hospital Pharmacies segment is projected to expand at 21.9% CAGR during 2023 - 2031.
By country, the Europe Antibody Drug Conjugates Market is categorized into the United Kingdom, Germany, France, Italy, Spain, and the Rest of Europe. Germany is projected to expand at 22.3% CAGR during 2023 - 2031.
Key players operating in the Antibody Drug Conjugates Market are GSK Plc, F. Hoffmann-La Roche Ltd, Pfizer Inc, Bristol-Myers Squibb Co, Johnson & Johnson, Takeda Pharmaceutical Co Ltd, AstraZeneca Plc, Astellas Pharma Inc, AbbVie Inc, Merck KGaA, Gilead Sciences Inc, BioNTech SE, Daiichi Sankyo Co Ltd, RemeGen Co Ltd, and ADC Therapeutics SA, among others.
- In Nov 2024, AstraZeneca constructed a US$1.5 billion manufacturing facility in Singapore dedicated to antibody drug conjugates (ADCs), which will improve the global supply of its ADC portfolio. ADCs are advanced treatments designed to deliver powerful cancer-fighting agents directly to cancer cells using targeted antibodies.
- In Aug 2024, Daiichi Sankyo announced the establishment of new subsidiaries in Mexico and Colombia. With these additions, the Daiichi Sankyo group was then present in a total of 32 countries and regions. Alongside its operations in Brazil, this expansion allowed Daiichi Sankyo to contribute to the healthcare of over 60% of the total population of 640 million in Latin America. This development further strengthened the foundation of their global innovative business expansion, particularly in the area of oncology products.
Contact Us
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com